Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 13/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30544472 | 1.00 | LPL (0.44) | LPLLIPGCYP3A4ATMPOLB | |
| SCHEMBL29634547 | 0.89 | LPL (0.44) | LPLLIPGPOLBCA1CA2 | |
| SCHEMBL14212260 | 0.89 | LPL (0.44) | LPLLIPGPOLBCA1CA2 | |
| SCHEMBL15335321 | 0.86 | LPL (0.42) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL5899518 | 0.86 | POLB (0.40) | CYP3A4ATMPOLBALDH1A1HSD17B10 | |
| SCHEMBL14746387 | 0.83 | ALDH1A1 (0.55) | LPLLIPGPOLBCA1CA2 | |
| SCHEMBL10074112 | 0.79 | LPL (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL10074115 | 0.79 | LPL (0.48) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL21731053 | 0.79 | CYP3A4 (0.39) | CYP3A4ATMPOLBALDH1A1HSD17B10 | |
| SCHEMBL5899619 | 0.79 | CYP3A4 (0.39) | CYP3A4ATMPOLBALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740948-A1 | PHARMACEUTICAL COMPOSITION COMPRISING 1,3-BENZODIOXOLE DERIVATIVE COMPOUND | Dong Wha Pharm. Co., Ltd. (KR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2025-10-23 | — | — | US | disclosed |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-28 | — | — | US | disclosed |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| CN-119816509-A | Novel iron-based compounds, method for the production thereof and use thereof as catalysts | 巴黎萨克雷大学 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1127060-B8 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2005-01-05 | — | — | EP | disclosed |
| US-20040133028-A1 | Hydroboronation process | COMMONWEALTH SCIENTIFIC | 2004-07-08 | — | — | US | disclosed |
| EP-1127060-B1 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2004-04-07 | — | — | EP | disclosed |
| US-6680401-B1 | BORON COMPOUNDS SUCH AS 4-(METHOXYMETHYL)-1,3,2-DIOXABOROLANE, USED AS COUPLERS OR CHEMICAL INTERMEDIATES FOR DRUGS, PESTICIDES OR IN COMBINATORIAL CHEMISTRY | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2004-01-20 | — | — | US | disclosed |
| EP-1127060-A4 | HYDROBORONATION PROCESS | COMMW SCIENT IND RES ORG (AU) | 2002-08-21 | — | — | EP | disclosed |
| EP-1127060-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000027853-A1 | HYDROBORONATION PROCESS | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2000-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | LPL 570/4885LIPG 661/4885CYP3A4 115/4885 |
| US-20250326746-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | LPL 4052/4885LIPG 3559/4885CYP3A4 4553/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | LPL 2/4885LIPG 17/4885CYP3A4 697/4885 |
| US-20040133028-A1 | Hydroboronation process | ALKBH3, HPD, HVCN1 | LPL 4659/4885LIPG 4522/4885CYP3A4 80/4885 |
| US-20250270215-A1 | IMIDAZOLE DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, TGFBR2 | LPL 3001/4885LIPG 1259/4885CYP3A4 3165/4885 |
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | LPL 2932/4885LIPG 449/4885CYP3A4 4459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.